Mullard, A. FDA approves 100th monoclonal antibody product. Nat. Rev. Drug Discov. 20, 491–495 (2021).

Article  CAS  PubMed  Google Scholar 

Rawat, P. et al. YAbS: The Antibody Society’s antibody therapeutics database. mAbs 17, 2468845 (2025).

Article  PubMed  PubMed Central  Google Scholar 

Chan, A. C., Martyn, G. D. & Carter, P. J. Fifty years of monoclonals: the past, present and future of antibody therapeutics. Nat. Rev. Immunol. 25, 745–765 (2025).

Article  CAS  PubMed  Google Scholar 

Sathish, J. G. et al. Challenges and approaches for the development of safer immunomodulatory biologics. Nat. Rev. Drug Discov. 12, 306–324 (2013).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wilkinson, I. & Hale, G. Systematic analysis of the varied designs of 819 therapeutic antibodies and Fc fusion proteins assigned international nonproprietary names. mAbs 14, 2123299 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Keri, D., Walker, M., Singh, I., Nishikawa, K. & Garces, F. Next generation of multispecific antibody engineering. Antib. Ther. 7, 37–52 (2024).

CAS  PubMed  Google Scholar 

Bates, A. & Power, C. A. David vs. Goliath: the structure, function, and clinical prospects of antibody fragments. Antibodies 8, 28 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Albayrak, G., Wan, P. K., Fisher, K. & Seymour, L. W. T cell engagers: expanding horizons in oncology and beyond. Br. J. Cancer 133, 1241–1249 (2025).

Article  PubMed  PubMed Central  Google Scholar 

Zhu, W. M. & Middleton, M. R. Combination therapies for the optimisation of Bispecific T-cell Engagers in cancer treatment. Immunother. Adv. 3, ltad013 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Van Wauwe, J. P., De Mey, J. R. & Goossens, J. G. OKT3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties. J. Immunol. 124, 2708–2713 (1980).

Article  PubMed  Google Scholar 

Jhajj, H. S., Lwo, T. S., Yao, E. L. & Tessier, P. M. Unlocking the potential of agonist antibodies for treating cancer using antibody engineering. Trends Mol. Med. 29, 48–60 (2023).

Article  CAS  PubMed  Google Scholar 

Lim, S. H., Beers, S. A., Al-Shamkhani, A. & Cragg, M. S. Agonist antibodies for cancer immunotherapy: history, hopes, and challenges. Clin. Cancer Res. 30, 1712–1723 (2024).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mayes, P. A., Hance, K. W. & Hoos, A. The promise and challenges of immune agonist antibody development in cancer. Nat. Rev. Drug Discov. 17, 509–527 (2018).

Article  CAS  PubMed  Google Scholar 

Paluch, C., Santos, A. M., Anzilotti, C., Cornall, R. J. & Davis, S. J. Immune checkpoints as therapeutic targets in autoimmunity. Front. Immunol. 9, 2306 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Fromm, G., de Silva, S. & Schreiber, T. H. Reconciling intrinsic properties of activating TNF receptors by native ligands versus synthetic agonists. Front. Immunol. 14, 1236332 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sedger, L. M. & McDermott, M. F. TNF and TNF-receptors: from mediators of cell death and inflammation to therapeutic giants — past, present and future. Cytokine Growth Factor Rev. 25, 453–472 (2014).

Article  CAS  PubMed  Google Scholar 

Saxton, R. A., Glassman, C. R. & Garcia, K. C. Emerging principles of cytokine pharmacology and therapeutics. Nat. Rev. Drug Discov. 22, 21–37 (2023).

Article  CAS  PubMed  Google Scholar 

Yen, M. et al. Facile discovery of surrogate cytokine agonists. Cell 185, 1414–1430.e19 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pekar, L., Krah, S. & Zielonka, S. Taming the beast: engineering strategies and biomedical potential of antibody-based cytokine mimetics. Expert Opin. Biol. Ther. 24, 115–118 (2024).

Article  CAS  PubMed  Google Scholar 

Lovewell, R. R., Langermann, S. & Flies, D. B. Immune inhibitory receptor agonist therapeutics. Front. Immunol. 16, 1566869 (2025).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dushek, O., Goyette, J. & van der Merwe, P. A. Non-catalytic tyrosine-phosphorylated receptors. Immunol. Rev. 250, 258–276 (2012).

Article  PubMed  Google Scholar 

Bucktrout, S. L., Bluestone, J. A. & Ramsdell, F. Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again. Genome Med. 10, 79 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thiel, K. W. & Giangrande, P. H. Therapeutic applications of DNA and RNA aptamers. Oligonucleotides 19, 209–222 (2009).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou, G. et al. Aptamers: a promising chemical antibody for cancer therapy. Oncotarget 7, 13446–13463 (2016).

Article  PubMed  PubMed Central  Google Scholar 

Lu, H., Cheng, Z., Hu, Y. & Tang, L. V. What can de novo protein design bring to the treatment of hematological disorders? Biology 12, 166 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Adams, C. S. et al. De novo design of protein minibinder agonists of TLR3. Nat. Commun. 16, 1234 (2025).

Article  PubMed  PubMed Central  Google Scholar 

Fontaine, T. et al. Structure elucidation of a human melanocortin-4 receptor specific orthosteric nanobody agonist. Nat. Commun. 15, 7029 (2024).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dunn, M. E. et al. Agonist antibody to guanylate cyclase receptor NPR1 regulates vascular tone. Nature 633, 654–661 (2024).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dostert, C., Grusdat, M., Letellier, E. & Brenner, D. The TNF family of ligands and receptors: communication modules in the immune system and beyond. Physiol. Rev. 99, 115–160 (2019).

Article  CAS  PubMed  Google Scholar 

Hehlgans, T. & Pfeffer, K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 115, 1–20 (2005).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Locksley, R. M., Killeen, N. & Lenardo, M. J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104, 487–501 (2001).

Article